JOHN FARMER to Coronary Artery Disease
This is a "connection" page, showing publications JOHN FARMER has written about Coronary Artery Disease.
Connection Strength
1.392
-
Strategies for multivessel revascularization in patients with diabetes: the FREEDOM trial. Curr Atheroscler Rep. 2014 Jul; 16(7):426.
Score: 0.268
-
High-density lipoprotein and atherosclerosis: the role of antioxidant activity. Curr Atheroscler Rep. 2012 Apr; 14(2):101-7.
Score: 0.230
-
Adjunctive interventions in myocardial infarction: the role of statin therapy. Curr Atheroscler Rep. 2008 Apr; 10(2):142-8.
Score: 0.174
-
Reversal of atherosclerosis with aggressive lipid lowering. Curr Atheroscler Rep. 2005 Mar; 7(2):86-7.
Score: 0.140
-
Raising high-density lipoprotein cholesterol: innovative strategies against an old adversary. Curr Atheroscler Rep. 2005 Mar; 7(2):88-94.
Score: 0.140
-
Atherosclerosis and inflammation. Curr Atheroscler Rep. 2002 Mar; 4(2):92-8.
Score: 0.114
-
Economic implications of lipid-lowering trials: current considerations in selecting a statin. Am J Cardiol. 1998 Sep 24; 82(6A):26M-31M.
Score: 0.090
-
Aggressive lipid therapy in the statin era. Prog Cardiovasc Dis. 1998 Sep-Oct; 41(2):71-94.
Score: 0.090
-
Evolving concepts of the role of high-density lipoprotein in protection from atherosclerosis. Curr Atheroscler Rep. 2011 Apr; 13(2):107-14.
Score: 0.054
-
Rationale for aggressive lipid lowering: evidence from clinical trials. Expert Rev Cardiovasc Ther. 2004 May; 2(3):305-9.
Score: 0.033
-
Progressive deterioration of coronary flow reserve after heart transplantation. Am Heart J. 1998 Sep; 136(3):504-9.
Score: 0.022
-
Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations (Lipoprotein and Coronary Atherosclerosis Study [LCAS]). Am J Cardiol. 1997 Aug 01; 80(3):278-86.
Score: 0.021
-
Baseline characteristics of subjects in the Lipoprotein and Coronary Atherosclerosis Study (LCAS) with fluvastatin. Am J Cardiol. 1994 May 26; 73(14):42D-49D.
Score: 0.017